Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus

Diabetes, Obesity & Metabolism
T HeiseH Haahr

Abstract

To evaluate the pharmacodynamic dose-response relationship of insulin degludec/insulin aspart (IDegAsp), a novel, soluble co-formulation of the ultra-long-acting basal insulin, insulin degludec (IDeg), with the rapid-acting prandial insulin (IAsp), across different doses in patients with type 1 diabetes (T1DM). This was a randomized, single-centre, double-blind, four-period, incomplete block, crossover trial. A cohort of 33 people with T1DM received single doses (0.4, 0.6 or 0.8 U/kg) of IDegAsp or the comparator, biphasic insulin aspart 30, in a randomized sequence of four treatment periods, each separated by a washout of 13-21 days. Pharmacodynamic response was assessed using a 26-h euglycaemic glucose clamp, with blood glucose stabilized at a target of 5.5 mmol/l (100 mg/dl). A rapid onset of action and a distinct peak attributable to IAsp was observed in the glucose infusion rate (GIR) profile, followed by a separate, flat and stable basal glucose-lowering effect attributable to the IDeg component. The mean area under the GIR curve over 24 h (AUC(GIR,0-24 h)), and the mean maximum GIR (GIR(max)) increased with increasing dose level of IDegAsp. A dose-response relationship for IDegAsp was demonstrated for AUC(GIR,0-24 h) and...Continue Reading

References

Oct 24, 2009·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
Mar 1, 2012·Diabetes Care·Eda CengizStuart A Weinzimer
Feb 15, 2014·World Journal of Clinical Cases·Carlton Robert FenzlJason Goldsmith
Jun 4, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tim HeiseHanne Haahr
Sep 3, 2014·Clinical Pharmacokinetics·Hanne Haahr, Tim Heise

❮ Previous
Next ❯

Citations

Jul 8, 2016·International Journal of Clinical Practice·A KumarJ S Christiansen
Feb 14, 2017·Diabetes Technology & Therapeutics·Thomas DanneJan Bolinder
Nov 2, 2019·Current Drug Targets·Ping WuHao Fang
May 13, 2020·Endocrine Reviews·Irl B HirschEugene E Wright
Jan 17, 2021·BMJ Open Diabetes Research & Care·Ilze Dirnena-FusiniSverre Christian Christiansen
Sep 18, 2021·Diabetes, Obesity & Metabolism·Ravi Retnakaran, Bernard Zinman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.